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Background: Hepatitis C virus (HCV) infection is a major risk factor for chronic hepatitis and hepatocellular carcinoma
(HCC); however, the mechanism of HCV-mediated hepatocarcinogenesis is not well understood. Insufficiency of PTEN
tumor suppressor is associated with more aggressive cancers, including HCC. We asked whether viral non-coding RNA
could initiate oncogenesis in HCV infected human hepatocytes. The results presented herein suggest that loss of
nuclear PTEN in HCV-infected human hepatocytes results from depletion of Transportin-2, which is a direct target of
viral non-coding RNA, vmr11.
Methods: The intracellular distribution of PTEN in HCV-infected cells was monitored by immunostaining and Western
blots of nuclear and cytoplasmic proteins. Effects of PTEN depletion were examined by comparing expression
arrays of uninfected cells with either HCV-infected or vmr11-transfected cells. Target genes suggested by array
analyses were validated by Western blot. The influence of nuclear PTEN deficiency on virus production was determined
by quantitative analysis of HCV genomic RNA in culture media of infected hepatocytes.
Results: Import of PTEN to the nucleus relies on the interaction of Transportin-2 and PTEN proteins; we show that
depletion of Transportin-2 by HCV infection or by the introduction of vmr11 in uninfected cells results in reduced
nuclear PTEN. In turn, nuclear PTEN insufficiency correlates with increased virus production and the induction of
γ-H2AX, a marker of DNA double-strand breaks and genomic instability.
Conclusion: An HCV-derived small non-coding RNA inhibits Transportin-2 and PTEN translocation to the nucleus,
suggesting a direct viral role in hepatic oncogenesis.
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Phosphatase and tensin homologue deleted on chromosome
10 (PTEN) is one of the most commonly targeted tumor
suppressor genes in human cancers, encoding a 403-
residues dual specificity phosphatase with both lipid and
protein phosphatase activities [1-5]. The lipid phosphatase
activity of PTEN is a central negative regulator of the
Phosphatidylinositol-3-kinase (PI3K) signal cascade for
cell growth and proliferation. Deregulation of PTEN has
been associated with a spectrum of metabolic disorders
related to hepatocarcinogenesis [6]. A recent report [7]
points to post-transcriptional silencing of PTEN by* Correspondence: akumar@gwu.edu
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unless otherwise stated.HCV core 3a protein as a possible mechanism of PTEN
deregulation.
Nuclear insufficiency of PTEN has been shown to con-
tribute to centromere destabilization and genomic instabil-
ity [8,9], a hallmark of cancer, and nuclear PTEN depletion
has been associated with more aggressive cancers [10-12].
In this study, we ask whether HCV infection initiates
nuclear PTEN insufficiency and, in particular, whether
viral non-coding RNA plays a part in regulating the
intracellular redistribution of PTEN protein. We present
evidence of inhibition of Transportin-2 by a viral non-
coding RNA (vmr11). This inhibition restricts nuclear
translocation of PTEN in HCV-infected human hepato-
cytes. We further show that restoring intracellular Trans-
portin-2 levels rescues wild-type levels of nuclear PTEN.
Based on the interaction between PTEN and Transportin-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of nuclear PTEN translocation where down-regulation of
Transportin-2 by vmr11 correlates with the nuclear exclu-
sion of PTEN protein in HCV-infected human hepatocytes.
Results
Restriction of nuclear PTEN in HCV-infected cells
We examined the distribution of PTEN by immunofluor-
escence staining in human primary hepatocytes, before
and after transfection with HCV1a genomic RNA [13].
Figure 1A (upper panels) shows a uniform distribution of
PTEN in uninfected cells, whereas staining of nuclear
PTEN was less uniformly distributed in HCV replicating
cells. Virus replication in this assay was marked with
immune staining for NS5A antigen (far right panel).
To quantitatively analyze the intracellular distribution
of PTEN protein, we performed Western blots of total
cell protein, and of the nuclear and cytoplasmic fractions
of HCV-infected cells (Figure 1B and 1C). There was
no noticeable change in PTEN protein levels when we
compared total cell proteins of HCV-replicating and
control cells (Figure 1B; virus replication was markedFigure 1 HCV replication in human hepatocytes. (A) Intracellular distribut
genomic RNA. The uninfected cells (left four panels) show uniform PTEN stain
Transfection efficiency of HCV genomic RNA was approximately 30%. (B) PTEN
1 μg H77 HCV1a genomic RNA, and the cells were collected at day five (U, unin
of protein was analyzed on 10% precast Protein Gel; numbers underneath each
viral core antigen (HCV Core). (C) Restriction of nuclear PTEN protein in HCV-i
(0.5, 1.0, 2.0 μg) of input HCV1a genomic RNA, cells were harvested 5 days po
analyzed by Western blot. GAPDH and Lamin B1 were loading controls respeby immunoblot for HCV core antigen). However, when
we compared PTEN protein levels in the nuclear and
the cytoplasmic fractions (Figure 1C), we observed
marked inhibition of nuclear PTEN in HCV-replicating
cells. These results suggest a progressive decline of nuclear
PTEN in cells transfected with increasing amounts of viral
genomic RNA (Figure 1C). The relatively unchanged levels
of cytoplasmic PTEN and gradual decline in nuclear
PTEN suggest, but do not prove, the deregulation of
intracellular distribution of PTEN as possible mechan-
ism of nuclear PTEN depletion in HCV-replicating
cells. We therefore asked whether viral small non-
coding RNAs might, directly or indirectly, modulate the
intracellular distribution of the PTEN protein.
HCV-derived small non-coding RNAs
The positive sense HCV RNA genome is replicated in
infected cells using the minus strand viral genomic RNA
as a template. We reasoned that the conserved hairpin-
loop structure of the minus strand genomic RNA, which is
not engaged in translation, could serve as possible source
of viral small non-coding RNAs (vmrs). To determineion of PTEN: Cells were visualized at day 3 post-transfection with HCV
ing; HCV replication is marked with NS5A antigen (far right panel).
protein in HCV-infected cells: 1 × 105 PPH cells were transfected with
fected; I, infected). Total cell protein was extracted using RIPA buffer; 20 μg
lane indicate the relative values of PTEN. HCV replication is marked with
nfected cells: 1 × 105 PPH cells were transfected with increasing amounts
st-transfection and 10 μg each of nuclear or cytoplasmic protein were
ctively, for the cytoplasmic or nuclear protein.
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to search the ~9,600 bp minus strand RNA genome for
structurally conserved hairpins that could act as putative
viral microRNA precursors. Sequence conservation at the
‘seed’ position in 37 GenBank HCV genomes as well as
the configuration geometry of the hairpin arm and loop
helped select 13 candidates, whose presence in HCV-
infected cells were validated with qRT-PCR (see Methods
and Additional file 1: Figure S1 (and Additional file 1:
Table S1, for details). Here we discuss the functional valid-
ation of the 22 nt vmr11 RNA that was abundantly
expressed in HCV infected human hepatocytes (Figure 2).Abundance of vmr11 varies with time post HCV infection
We reasoned that the HCV-derived vmr11 would be ex-
pected to accumulate with increasing duration of virus
replication and increased input of viral genomic RNA.
To test the prediction, we performed qRT-PCR analyses
of vmr11 RNA in human hepatocytes (transfected with
HCV genomic RNA) at 3, 6 and 12 days post-transfection
(Figure 3A, B) and repeated the analyses in cells trans-
fected with increasing amounts of HCV genomic RNA
(Figure 3C). We observed the highest accumulation of
vmr11 at day six post-transfection of human hepatocytes
(Figure 3A). As reported earlier [13] HCV replication can
be maintained for weeks with serial passages through
naïve hepatocyte cultures. However, viral RNA replication
in continuous cultures declines after a peak at six days, as
does the HCV genomic RNA derived vmr11 (Figure 3A).
The accumulation of vmr11 RNA also correlated with
increasing amounts of viral genomic RNA transfected into
human hepatocytes (Figure 3C). Serving as a control,
we observed a parallel increase in host cell miRNA-141
(Figure 3B). It was previously reported that HCV replica-
tion correlates with miR-141-mediated post-transcriptional
silencing of the DLC-1 tumor suppressor [14]. Conversely,
expression of miR-16, which is not sensitive to HCV
replication, remained unchanged in HCV-infected cells.
While the mechanism behind the processing of the 22
nt vmr11 sequence is not completely understood, the
increased production of vmr11 in parallel with viral
replication indicates that vmr11 is derived from the
HCV genomic RNA.Figure 2 The HCV derived viral small RNAs. (A) Quantitation of vmrs: RT-PCR
HCV genomic RNA, and only minimal change in vmr20. (I, infected; U, uninfecte
marker served as internal reference). (B) Structure of vmr11 RNA: Predicted secoExpression arrays of human hepatocytes transfected
with vmr11 “mimic” oligonucleotides as compared to
HCV-infected cells
To identify vmr11 target genes that may be involved in
limiting nuclear PTEN translocation, we contrasted changes
in gene expression in HCV-infected hepatocytes (shown
as H77-1, -2 and -3 in three independent infections), and
separately in cells transfected with vmr11 “mimic” oligonu-
cleotides (mimic-1, -2 and -3), against uninfected (control)
cells, using the Agilent microarray platform (Additional
file 2). For each comparison, differential expression ana-
lyses revealed several hundred up- and down-regulated
genes that could serve as potential markers for HCV
infection-associated liver disease. Notably, the qualitative
and quantitative changes in gene expression of cells
transfected with vmr11 “mimic” oligonucleotides (vmr11
‘mimic’ is defined as a synthetic 22nt oligomer identical in
sequence with the ‘wild type’ vmr11) were similar to those
in HCV-infected cells (Additional file 1: Figure S2).
Functional analyses using the KEGG database [15]
revealed several pathways enriched among differentially
expressed genes and in common between the two sets of
comparisons (H77 and ‘mimic’). In particular, genes in-
volved in lipid biosynthesis, intracellular signaling, and
control of cell growth and patterning were enriched among
the up-regulated genes; whereas genes involved in the regu-
lation of cell motility, and members of the peroxisome
proliferator activated receptors (PPAR) signaling pathway
involved in lipid metabolism, were over-represented among
the down-regulated genes (Additional file 3).
Import of nuclear PTEN is sensitive to intracellular
Transportin-2 levels
Although the array results do not directly identify the
vmr11-modulated genes, target analysis of 3’ UTRs of dif-
ferentially down-regulated genes using the PITA prediction
program [16] identified several potential vmr11 targets
(Additional file 1: Table S2), including Transportin-2
(TNPO2, also known as Karyopherin β − 2b). Transportin-
2 is known to interact with nucleocytoplasmic shuttling
proteins and to regulate their nuclear import [17-20].
Since both the results of expression arrays and the vmr11
targets predicted by PITA analysis of 3′ UTRs suggested
that vmr11 could target Transportin-2 (TRN-2) expression,results show robust increase in vmr11 levels six days post-transfection with
d). As control, miR-122 level is minimally changed upon viral infection. (18S
ndary structure of vmr11 precursor. Mature vmr11 RNA is shown in red.
Figure 3 Viral small non-coding RNA in HCV replicating cells. (A) Expression of vmr11 RNA: 1 × 105 PPH cells were transfected with 1 μg of
HCV1a genomic RNA and harvested on days 3, 6 and 12 post-transfection; vmr11 was monitored by qRT-PCR (normalized to miR-16, which does
not change with viral infection). (B) MicroRNA-141 expression in cells transfected with HCV genomic RNA: qRT-PCR analysis of miR-141 in PPH
cells transfected with increasing amounts of viral genomic RNA. (C) vmr11 expression with increasing HCV genomic RNA: qRT-PCR of vmr11 RNA
in PPH cells transfected with increasing amounts of input viral genomic RNA (0.5, 1 and 2 μg) was analyzed five days post-transfection.
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vmr11 oligonucleotides (Figure 4). We confirmed that
TRN-2 was inhibited in human hepatocytes when the
intracellular levels of vmr11 “mimic” oligonucleotides
were artificially increased by transfection (Figure 4A,
second lane from left). Countering the effects of vmr11
with the antisense oligonucleotides (vmr11-Ctl, third
lane) restored Transportin-2 protein levels. As controls,
we observed the inhibition of TRN-2 protein by siRNA
knockdown (Si-TRN2, fourth lane from left), which was
not seen in cells treated with scrambled siRNA (Si-Ctl,
fifth lane from left). Restoring TRN-2 by transfecting
Transportin-2 cDNA following siRNA knock down (Si-
TRN-2 + TRN-2 CFP, far right lane) rescued intracellular
Transportin-2 protein. Thus, introducing vmr11 oligonu-
cleotides in uninfected cells appears to be sufficient to
down-regulate Transportin-2 protein levels.
Next, we asked whether the down-regulation of TRN-2
influences PTEN protein levels in the nucleus (Figure 4B).
Western blots of nuclear PTEN show that knock-down
of TRN-2 with siRNA (Si-TRN-2, third lane from left)
is as effective in limiting nuclear PTEN as vmr11 ‘mimic’
oligonucleotides alone (second lane from left). As a
control, scrambled siRNA (Si-Ctl, fourth lane from left)
had no effect on nuclear PTEN restriction. Interestingly,restoring the intracellular TRN-2 by introducing Trans-
portin-2 cDNA, following siRNA knock down of TRN-2
(Si-TRN-2 + TRN-2 CFP, far right lane), restored nuclear
PTEN protein levels. These results indicate that the
import of nuclear PTEN depends on Transportin-2.
To determine if the direct TRN-2-PTEN interaction is
at least partially responsible for the nuclear import of
PTEN, we performed immunoprecipitation assays. As
shown in Figure 4C, the PTEN antibody pull-down fraction
(but not IgG controls) showed TRN-2-PTEN interaction.
These results suggest that the nuclear translocation of
PTEN depends on its binding to Transportin-2.
To further explore the mechanism of restriction of
nuclear PTEN in TRN-2 deficient cells, we examined
the intracellular distribution of PTEN in cells either
transfected with vmr11 oligonucleotides or in which
TRN-2 was depleted by transfection of siRNA. As a
control, immunofluorescent staining of mock- transfected
cells and cells transfected with scrambled siRNA (si-Ctl)
showed a uniform intracellular distribution of both
PTEN (green FITC stain) and TRN-2 (Texas red).
Interestingly, in TRN-2-deficient cells (either due to
vmr11, or by si-TRN-2 knock-down), the PTEN-TRN-
2 complex appears to be restricted to the nuclear
membrane area (Figure 4D), suggesting that the nuclear
Figure 4 Transportin-2 is required for PTEN translocation to the nucleus. (A) Transportin-2 protein is inhibited by vmr11: Uninfected PPH
cultures were transfected with 50 nM oligonucleotides (from left to right): scrambled vmr11 (Ctl), vmr11 mimic (vmr11), vmr11 mimic plus vmr11-
antagomir (vmr11-Ctl), TRN-2 siRNA (Si-TRN-2), scrambled siTRN-2 (Si-Ctl) and siTRN-2 plus TRN-2 cDNA expression vector (Si-TRN-2 + TRN2-CFP).
Western blots of TRN-2 protein from cells harvested 48 hours post-transfection were quantitated from three independent assays using β-Actin as
loading control. (B) Nuclear PTEN is restricted by vmr11 or siTRN-2 knock-down: PPH cultures were transfected with 50 nM oligonucleotides (from
left to right): scrambled vmr11 (ctrl), vmr11 “mimic” (vmr11), si-TRN2, scrambled si-TRN2 (si-ctl) or 1 μg TRN-2 cDNA expression vector following
TRN-2 knock-down (si-TRN2 + TRN2-CFP). Transfections were repeated twice at 24 hour intervals and cells were harvested at 48 hour post-transfection;
Western blot of nuclear PTEN was quantitated (with Lamin B1 as loading control); results shown are from three independent assays.
(C) Transportin-2-PTEN protein interaction: Immunoprecipitates with PTEN antibody or IgG controls were analyzed by Western blot for PTEN
or TRN-2 protein. PTEN-TRN-2 protein interaction is shown in the far right lane. (D) Suboptimal PTEN-Transportin-2 protein complex is restricted
at nuclear membrane: Human primary hepatocytes were transfected with vmr11, Si-TRN2 and Si-Ctl oligonucleotides (50 nM of vmr11 mimic,
twice at 0 hour and 24 hour). Cells were processed at 48 hrs post-transfection. PTEN is stained with FITC and TRN-2 with Texas Red.
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TRN-2 protein complex.
Functional domains of the HCV-derived vmr11
To determine ‘functional domains’ of vmr11 required
for interaction with its TRN-2 target site, we examined
base substitution mutants of vmr11 (Figure 5A, upper
panel) and compared the effects on TRN-2 silencing and
consequent restriction of nuclear PTEN by Western blot
(Figure 5A, lower panel). In contrast with miRNA target
recognition [21], the extreme 5′-sequence of vmr11 appears
to be less critical for its TRN-2-target recognition. Indeed,
inhibition of TRN-2 by vmr11 mutants 1 and 2 was similar
to the wild type vmr11. Substitutions of nucleotides 7 and 8
(mutant 3) or nucleotides 9 and 10 (mutant 4), on the other
hand, showed minimal inhibition of TRN-2, suggesting thatnucleotides 7-10 of vmr11 contribute to the recognition
of the TRN-2 target site. For the most part, nuclear
PTEN protein levels also declined in parallel with the
vmr11-targeted inhibition of TRN-2. As an exception, in
cells transfected with mutant 2 (vmr11 base substitution
from C4A5 to G4U5) the depletion of nuclear PTEN
does not correlate with inhibition of Transportin-2. This
finding suggests that mechanisms other than the TRN-
2-PTEN interaction may contribute to restricting the
nuclear PTEN translocation.
Replication of HCV is positively correlated with restriction
of nuclear PTEN
Experiments described thus far utilized vmr11 or vmr11
mutant oligonucleotides to artificially increase intracellu-
lar concentrations of vmr11. Next, we asked whether
Figure 5 Domains of vmr11 RNA required for PTEN or TRN-2 inhibition. (A) vmr11mutants (upper panel): Base substitutions are shown in
red. Western blots of PTEN and TRN-2 proteins (shown in lower panel): PPH cultures were transfected (twice, at 0 and 24 hours) with 50 nM vmr11
‘mimic’ or one of the seven vmr11 mutants as indicated; total cell protein (for TRN-2), or the nuclear protein (for PTEN) was analyzed by Western blots.
TRN-2 or PTEN protein levels were determined from two independent experiments, shown below each lane. β-actin or Lamin B1 was used as loading
controls for TRN-2 and PTEN, respectively. (B) Virus production is positively correlated with loss of nuclear PTEN: 105 PPH cells each were transfected
with 1 μg HCV genomic RNA. A day later the cultures were either mock-transfected or transfected with vmr11 ‘mimic’ or with one of the seven vmr11
mutants (indicated in panel A). The oligonucleotide transfections were repeated twice (at 24 and 48 hour). Virus released in the culture media was
harvested at 24-hour intervals as indicated. Viral RNA was analyzed by qRT-PCR. All viral RNA levels shown were normalized to the control,
‘mock transfected’ cells at 24 hour. (C) Loss of Nuclear PTEN and TRN-2 protein levels in cells transfected with vmr11 or vmr11 mutants: PTEN
and TRN-2 proteins from the same cultures where virus released into the culture medium was quantitated (panel B), were analyzed by Western blots.
Relative values of nuclear PTEN or TRN-2 proteins are shown below each lane.
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replicating cells would influence TRN-2 protein levels
and limit nuclear PTEN. Significantly, such assays allowed
us to address whether virus production (HCV genomic
RNA recovered from the culture medium of infected cells)
increased in response to limiting nuclear PTEN protein.
To compete vmr11 RNA in vivo, we transfected the
various vmr11 mutants (shown in Figure 5A) into HCV-
infected human hepatocytes. As shown (Figure 5B), base
substitutions at nucleotides 7-10 (vmr11 mutants 3 and
4) that lost the capacity to recognize the TRN-2 target
site, and hence showed no inhibition of TRN-2 protein
or nuclear PTEN, minimally influenced HCV production.
By contrast, vmr11 mutants (1, 2, 5, 6 and 7) that appar-
ently do not interfere with TRN-2-target recognition, and
hence allow the inhibition of TRN-2 and nuclear PTEN,
favored virus production. These results suggest that deple-
tion of nuclear PTEN favors virus production. Western
blots of nuclear PTEN and TRN-2 proteins from the same
cells that were scored for virus production are shown in
Figure 5C. Overall, the results suggest that reduced levels
of nuclear PTEN protein in HCV infected cells favors
virus production; and that PTEN can be restored
in vivo by the introduction of competing vmr11 mutant
oligonucleotides.
Depletion of nuclear PTEN correlates with increased
γ −H2AX
Nuclear insufficiency of PTEN has previously been shown
to destabilize the centromere complex and to lead to
DNA double strand brakes (DSB) [8]. Accordingly, we
asked if the loss of nuclear PTEN in HCV infected cells
correlated with DSB, a hallmark of genomic instability.
We assessed the level of DSBs by utilizing antibodies to
the phosphorylated form of histone H2AX (γ-H2AX), a
commonly used marker for DSBs [22,23]. Western blots
of HCV-infected hepatocytes showed increased γ-H2AX
levels as compared to uninfected hepatocytes (Figure 6A,
second lane from the left). Consistent with the results
shown in Figure 4B, introducing vmr11 “mimic” oligo-
nucleotide in uninfected cell was sufficient for the
induction of γ-H2AX (Figure 6A, third lane from the
left). To validate that the vmr11-mediated inhibition of
nuclear PTEN is in part responsible for inducing γ-H2AX,
we countered the effects of vmr11 in vivo by introducing
antisense vmr11 oligonucleotides in HCV-infected human
hepatocytes and in the control cells transfected with
vmr11 ‘mimic’ oligonucleotides. The results shown in
Figure 6A suggest that the induction of γ-H2AX in PTEN-
deficient cells is due to the intracellular vmr11 RNA.
Analysis of vmr11 base-substitution mutants (Figure 5A)
allowed the functional validation of vmr11 domains that
are required for the inhibition of nuclear PTEN. It was
of interest therefore, to test whether introducing vmr11mutants would also induce changes in γ-H2AX levels
in uninfected cells. As illustrated in Figure 6B base-
substitution mutants of vmr11 (mutants 2, 3 and 4)
that are less likely to inhibit nuclear PTEN protein
levels do not induce γ-H2AX to the same extent as the
wild type vmr11. Overall, the results implicate PTEN
nuclear insufficiency to the induction of γ-H2AX.
In an attempt to correlate the effects of HCV infection or
transfection with vmr11 RNA to γ-H2AX induction in vivo,
we compared immunostaining of γ-H2AX in human hepa-
tocytes either infected with HCV or transfected with vmr11
‘mimic’ oligonucleotides. Immunostaining for NS5A viral
antigen identified the HCV-infected cells (Figure 6C).
Visual inspection of the HCV-infected cells and control
cells that were transfected with vmr11 ‘mimic’ oligonucleo-
tides identified relatively enhanced γ-H2AX staining nuclei.
Overall, these results are consistent with the interpretation
that depletion of nuclear PTEN in human hepatocytes,
either due to HCV infection or by artificially increasing
intracellular vmr11 RNA in uninfected cells, results in
the induction of γ-H2AX.
To conclude, inhibition of Transportin-2 by the viral
non-coding RNA, vmr11 limits PTEN translocation to the
nucleus and is sufficient to induce γ-H2AX an indicator
of DSB and genomic instability in HCV-infected human
hepatocytes (an overview of the results, is depicted in
Figure 6D).
Discussion
One of the critical steps in virus life cycle is their ability
to modulate host defenses that favor virus propagation.
For oncogenic virus such as HCV, a challenge is to
define direct viral role in the depletion of PTEN tumor
suppressor that correlates with more aggressive cancer,
including HCC. The results described here suggest a novel
mechanism of regulation of intracellular distribution of
PTEN protein by viral non-coding RNA directed suppres-
sion of Transposrtin-2. Viral non-coding RNA mediated
inhibition of Transportin-2 and the loss of nuclear PTEN
in HCV-infected human hepatocytes implicate a direct
viral role in oncogenic transformation. Consistent with
that interpretation is our observation that HCV mediated
nuclear insufficiency of PTEN correlates with DSB and
genomic instability and efficient virus production.
Small RNA-based mechanisms, such as RNA interference
(RNAi), play important roles in regulating the course of
viral infection and viral pathogenesis in plants and animals
[24-29]. Examples of virus-derived microRNAs have been
reported in the human cytomegalovirus, Epstein Barr
virus, Kaposi Sarcoma-associated virus, peach latent mosaic
viroid [30,31], as well as in two viruses with RNA genomes,
HIV-1 and BLV [27,32]. An earlier study [33] employing
high-throughput sequencing predicted, albeit did not
functionally validate, the presence of small viral RNAs
Figure 6 Induction of γ-H2AX in HCV replicating or vmr11 transfected cells. (A) γ-H2AX is induced by vmr11 in HCV infected cells: (from left
to right), Human hepatocyte cultures were either mock transfected (Control), or transfected with 1 μg HCV1a (H77) genomic RNA, or with 50 nM
vmiR11 “mimic” oligonucleotides. As controls, HCV1a genomic RNA or vmr11-transfected cultures were treated with 50 nM vmr11 antagomir (“LNA”).
The cells were harvested 3 days post-transfection and analyzed by Western blot for γ-H2AX. The numbers beneath indicate relative values of γ-H2AX
normalized to β-Actin loading control. (B) Induction of γ-H2AX correlates with vmr11 mutants that inhibit nuclear PTEN protein: Western blots (of cells
transfected with vmr11 oligonucleotides, similar to the results shown in panel A) were compared with changes in γ-H2AX levels in cells transfected
with either the WT vmr11, or with one of the vmr11 mutants (shown in Figure 5A). The numbers underneath represent relative values of γ-H2AX
protein normalized to β-Actin loading control (C) Immunofluorescence staining of γ-H2AX (FITC) in HCV replicating or vmr11 transfected cells: Human
hepatocytes were either transfected with HCV1a (1 μg viral genomic RNA; HCV replication is marked with NS5A viral antigen (Texas red stain),
or transfected with vmr11 (50 nM) oligonucleotides, and processed for immunofluorescence viewing after 48 hours. γ-H2AX was stained with FITC and
NS5A with Texas Red. Stained cell foci shown are at magnification 20x and 100x (inset). (D) Mechanism of regulation of nuclear PTEN deficiency by
HCV: Schematic of nuclear PTEN restriction in HCV-infected cells that is mediated by translational silencing of Transportin-2 with vmr11.
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RNA of several viruses, including HCV. By analyzing
the conserved hairpin-loop structures of the HCV minus
strand genomic RNA as a source of viral microRNA,
we identified novel viral small non-coding RNA, vmr11,
and have functionally validated the vmr11-dependent
restriction of nuclear PTEN.
PTEN is a haploinsufficient tumor suppressor; partial
depletion of PTEN is expected to profoundly influence
cell cycle deregulation and genomic instability, hallmarks
of oncogenic susceptibility. A number of mechanisms have
been proposed to explain nucleocytoplasmic partitioning
of PTEN [34-36]; however, there are no examples of
PTEN restriction mediated by a human oncogenic virus.
PTEN lacks both the conventional nuclear import (nuclear
localization signal, NLS) and the nuclear export (NES)
motifs [1,35]. No mutation has been reported among allthe cases of nuclear PTEN ‘mis-localization’ examined [1],
leaving open the possibility that nuclear translocation of
PTEN may be regulated by ‘non-genetic’ mechanisms
such as protein-protein interaction involving TRN-2.
PTEN deregulation plays a significant role in hepato-
pathogenesis [37,38]. The proposed role of HCV core 3a
in modulating the formation of PTEN-dependent large
lipid droplets in hepatocytes [7] implicates a direct viral
role in liver disease. Adding to these studies, the results
described herein support a novel mechanism for regulation
of PTEN translocation to the nucleus in HCV-infected
cells. Specifically, nuclear insufficiency of PTEN in HCV-
infected cells results from the depletion of Transportin-2,
which is mediated by a novel viral non-coding RNA,
vmr11. Reduced levels of Transportin-2 in cells that are
either transfected with vmr11 ‘mimic’ oligonucleotides, or
suffer siRNA knock-down of endogenous TRN-2, restrict
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membrane. Collectively, these findings point to a novel
mechanism of regulation of intracellular distribution of
PTEN that is mediated by Transportin-2, a direct target of
vmr11. The observation that the TRN-2-PTEN protein
complex is restricted at the nuclear membrane leaves
open the possibility that factor(s) other than protein-
protein interaction may be required for the PTEN
translocation to the nucleus.
Perhaps the most intriguing consequence of nuclear
PTEN insufficiency in HCV-infected cells is the induction
of γH2AX, a major player in the recognition and repair
of DNA double-strand breaks (DSB) and a hallmark of
genomic instability and cancer susceptibility [8,39,40].
We observed enhanced staining foci of γH2AX-positive
cells in HCV-infected or vmr11-transfected human hepa-
tocytes. Whether DSB related to the nuclear PTEN insuf-
ficiency in HCV infection serve as an early indicator
of HCV infection-associated hepatocellular carcinoma
can be pursued in future studies in an animal model
of HCV-infection associated HCC.Methods
Post-attachment primary hepatocytes (PPH)
A sustained primary human hepatocytes culture system
was recently described [13]. Briefly, a co-culture of Hepatic
Stellate cell line (CFSC-8B) was used as a ‘feeder layer’, to
provide the extracellular matrix for efficient attachment
of human primary hepatocytes suspension. The co-culture
was maintained in a serum-free Hepatocyte-Defined
Medium (HDM) for 30 days, during which the stellate
cells (that require serum for their replication) are largely
depleted. The primary human hepatocytes form “spher-
oids” that can be dispersed (with 0.05% trypsin treatment)
and propagated as monolayers (independent of stellate
cells), as ‘Post-attachment Primary Hepatocytes’ (PPH) in
HDM supplemented with 1% FBS. The PPH cultures are
dispersed with 0.05% trypsin and reseeded at 1:3 dilutions
at weekly intervals.Bioinformatics prediction of HCV small non-coding RNAs
The 9,646 bp negative sense HCV type 1 genome (Gen-
Bank accession: NC_004102) was divided, starting every
20 bp, into fixed size segments of length L = 70 (80, 90
and 100). RNAfold [41] was employed to test each short
sequence to determine stable hairpin structures that can
form viral small RNA precursors. Hairpins that scored
in the top 5% of the score distributions (determined by
comparison to simulated random samples) were analyzed
for conserved secondary structure by comparing 37 HCV
type 1 complete genome sequences. Lastly, putative viral
microRNA sequences were determined starting from
conserved sequences 7 bp or longer (‘seeds’) that couldbe extended to mature 20-25 viral small RNAs (see
Additional file 1 for details).
Transfection of PPH using H77 run-off transcript
pCV-H77c plasmid DNA was linearized for run-off tran-
scription of full length genomic RNA using T7 Ribomax
Express (Promega). 5×105 PPH cells were transfected with
1 μg of the H77 transcript using the Fugene 6 (Promega)
procedure. Virus replication was monitored by quantita-
tion of genomic equivalents (GE) of HCV RNA or by
immune blotting for NS5A or HCV core antigens.
Real time Quantitative PCR of viral small RNAs
1 μg of total RNA was reverse-transcribed using Quanti-
Mir RT Kit (System Biosciences). The cDNA was diluted
(100-fold) and amplified using PCR Supermix (Invitrogen)
or iTaq SYBR Green Supermix with Rox (Bio-Rad) on
GeneAmp PCR System 9700 or on ABI 7300 Real Time
PCR system.
Subcellular protein fractionation and Western blot
PPH cells were lysed with either RIPA buffer supple-
mented with 1X protease inhibitor cocktail (Roche), or
with NE-PER nuclear and cytoplasmic extraction reagents
(Thermo Pierce) for fractionations of nuclear or cytoplas-
mic proteins. Normally, 10 μg of protein was analyzed on
10% precast Mini-PROTEIN gel (BIO-RAD). The gels
were transferred to PVDF membrane, blocked with 5%
non-fat milk and probed with antibodies against PTEN
(ab#79156 1:1000), GAPDH (ab8245, 1:5000), Lamin-B1
(ab#16048, 1:500), HCV core (ab50288, 1:1000) or γ-
H2AX (ab11174, 1:1000).
Immunostaining
5×104 of HCV-infected or uninfected PPH cells were
seeded into six-well plates with sterilized cover glasses
one day before staining. The cells were washed with PBS
and fixed with 4% paraformaldehyde, washed and perme-
abilized with methanol at -20°C, blocked with 1% BSA and
stained with primary antibody against PTEN (ab32199,
1:100) and NS5A (ab20342, 1:100); followed by FITC or
Texas Red conjugated secondary antibodies.
Quantitation of virus from the culture medium of
infected cells
QIAamp Viral RNA Mini Kit (QIAGEN) was used to
extract RNAs from 140 μl of the culture medium of
HCV–infected (or control) cells. The cDNA was prepared
using QuantiTect Rev Transcription Kit (QIAGEN) and
was analyzed with primers that target the 5’ end of HCV
(positive sense) genomic RNA. Primer sequences are H77-
QRT-Forward (TGTGGAGCTGAGATCACTGG) and
H77-QRT-Reverse (CCGCCTTATCTCCACGTATT).
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All Quantitative Real time PCR and densitometry data
were analyzed using Microsoft Excel 2010.
RNA labeling and array hybridization
Sample labeling and array hybridization were performed
according to the Agilent One-Color Microarray-Based
Gene Expression Analysis protocol (Agilent Technology).
Data analysis
The Agilent Feature Extraction software (version 11.0.1.1)
was used to analyze acquired array images. Quantile
normalization and subsequent data processing were per-
formed with the GeneSpring GX v12.0 software package
(Agilent Technologies). Differentially expressed mRNAs
were identified through Fold Change filtering (cutoff 2.0).
Pathway analyses were performed using the standard
enrichment computation method. Lastly, 3′UTRs of Gen-
Bank RefSeq genes for vmr11 putative target analysis with
PITA were extracted from the UCSC Genome Browser
tables. (Details are provided in Additional file 1).
Additional files
Additional file 1: Prediction of small non-coding RNAs from HCV
genomic RNA. Figure S1. Schematic representation for predicting
conserved structural domains of HCV1a genomic RNA and the mature
vmr sequences. Table S1. Candidate vmr sequences were derived from
the HCV1a negative sense genomic RNA. Figure S2. Gene expression in
human hepatocytes transfected with vmr11 ‘mimic’ are similar to those
in HCV infected cells. (A) Down-regulated genes. (B) Up-regulated genes.
Table S2. vmr11 targets in HCV infected (H77) and vmr11 transfected
hepatocytes, predicted by PITA. Figure S4. vmr11binding sites on the
TRN-2 3′UTR. Vmr11 sequence is shown in red, with the seed region in
lowercase letters, PITA-predicted binding site is underlined.
Additional file 2: Differentially expressed genes in HCV infected
vmr11 RNA transfected human hepatocytes.
Additional file 3: Genes enriched in HCV infected and vmr11
RNA transfected human hepatocytes. Inhibition of nuclear PTEN in
HCV-infected human hepatocytes, by Bao et al.
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